BioSpace News Archive

Business

Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

Protara Therapeutics, Inc. today announced financial results for the fourth quarter and year ended December 31, 2021.

March 9, 2022
·
12 min read
Pharm Country

Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch

Akari Therapeutics, Plc today announced new preclinical data published in Frontiers in Pharmacology demonstrating that Akari’s pipeline candidate votucalis has potential as a treatment for pain and itch associated with conditions such as atopic dermatitis, psoriasis and neuropathic pain.

March 9, 2022
·
6 min read
Business

BrainsWay Reports Fourth Quarter and Full-Year 2021 Financial Results and Operational Highlights

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, reported fourth quarter and full year 2021 financial results and provided an operational update.

March 9, 2022
·
11 min read
Business

Syros to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 15, 2022

Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, March 15, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update.

March 9, 2022
·
1 min read
Biotech Bay

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the company will make seven oral presentations at the upcoming American Association for Cancer Research Annual Meeting 2022 being held April 8-13, 2022 in New Orleans, Louisiana.

March 9, 2022
·
7 min read
ZYUS Life Sciences Awarded EU-GMP Certification, Enables Expansion into Rapidly Growing Global Medical Cannabinoids Markets

ZYUS Life Sciences Inc., a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced that the company’s Canadian manufacturing facility has been awarded EU-Good Manufacturing Practice certification.

March 9, 2022
·
5 min read
Business

insitro and Genomics England Announce Partnership to Provide Multimodal Search Capabilities and Empower Data Exploration and Derivation of Novel Insights

As part of the collaboration, insitro will deploy its machine-learning capabilities on Genomics England’s histopathology images and accompanying genetic data to learn a multimodal representation that captures the fine grained semantic structure in this high-dimensional clinical data.

March 9, 2022
·
5 min read
Drug Development

Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that the first patient was dosed in its Phase 1/2 B-LIEVE dose-confirmation clinical trial of FLT180a for the treatment of hemophilia B.

March 9, 2022
·
9 min read
Pharm Country

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Genenta Science will present clinical data from its Phase 1/2a dose-escalation study of its clinical-stage candidate Temferon™ in patients with glioblastoma multiforme (GBM) who have an unmthylated MGMT gene promotor (uMGMT-GBM) at the annual meeting of the American Association for Cancer Research.

March 9, 2022
·
2 min read
Drug Development

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma.

March 9, 2022
·
7 min read